Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A Shorter Regimen for Rifampin-Resistant Tuberculosis.

McCaw ZR, Meng Z, Wei LJ.

N Engl J Med. 2019 Sep 12;381(11):e22. doi: 10.1056/NEJMc1905782. No abstract available.

PMID:
31509686
3.
4.

A Shorter Regimen for Rifampin-Resistant Tuberculosis.

Tornheim JA, Udwadia ZF, Gupta A.

N Engl J Med. 2019 Sep 12;381(11):e22. doi: 10.1056/NEJMc1905782. No abstract available.

PMID:
31509687
5.

A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.

Nunn AJ, Phillips PPJ.

N Engl J Med. 2019 Sep 12;381(11):e22. doi: 10.1056/NEJMc1905782. No abstract available.

PMID:
31509688
6.

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A.

N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283.

7.
8.

The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.

Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, Gourgiotis D, Tsolia MN.

Clin Infect Dis. 2007 Sep 15;45(6):715-22. Epub 2007 Aug 6.

PMID:
17712755
9.

High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.

Chesov D, Ciobanu N, Lange C, Heyckendorf J, Crudu V.

Eur Respir J. 2017 Oct 12;50(4). pii: 1701340. doi: 10.1183/13993003.01340-2017. Print 2017 Oct. No abstract available.

10.

Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure.

Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE Jr.

JAMA. 1985 May 17;253(19):2847-9.

PMID:
3989958
11.

Latent tuberculosis infection in children: a call for revised treatment guidelines.

Finnell SM, Christenson JC, Downs SM.

Pediatrics. 2009 Mar;123(3):816-22. doi: 10.1542/peds.2008-0433.

PMID:
19255008
12.

Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array.

Huang WL, Hsu ZJ, Chang TC, Jou R.

Clin Microbiol Infect. 2014 Sep;20(9):O542-9. doi: 10.1111/1469-0691.12517. Epub 2014 Feb 2.

13.

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.

Srivastava S, Sherman C, Meek C, Leff R, Gumbo T.

Antimicrob Agents Chemother. 2011 Nov;55(11):5085-9. doi: 10.1128/AAC.00269-11. Epub 2011 Sep 6.

14.

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.

[No authors listed]

Monaldi Arch Chest Dis. 1994 Sep;49(4):327-45.

PMID:
8000420
15.
16.

Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Park SK, Kim JH, Kang H, Cho JS, Smego RA Jr.

Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2.

17.

Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation.

Nikolayevsky V, Brown T, Balabanova Y, Ruddy M, Fedorin I, Drobniewski F.

J Clin Microbiol. 2004 Oct;42(10):4498-502.

18.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063
19.
20.

Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.

Supplemental Content

Support Center